MLLCF (Molecular Partners AG) Total Payout Ratio: 0.00 (As of Jul. 09, 2026)

What is Molecular Partners AG Total Payout Ratio?

Molecular Partners AG MLLCF 25 Total Payout Ratio is 0.00 as of Jul. 09, 2026. GuruFocus rates MLLCF with a GF Score™ of 25/100 and a GF Value™ of $0.44 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Molecular Partners AG's current Total Payout Ratio is 0.00.

Molecular Partners AG Total Payout Ratio Related Terms

Molecular Partners AG Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Molecular Partners AG's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecular Partners AG Total Payout Ratio Chart

Molecular Partners AG Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Payout Ratio

Get a 7-Day Free Trial

0.81

0.01

0.00

0.32

0.00

Molecular Partners AG Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Payout Ratio	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

MLLCF vs VRTX, REGN, ALNY: Total Payout Ratio Comparison

For the Biotechnology subindustry, Molecular Partners AG's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Molecular Partners AG Total Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's Total Payout Ratio falls into.

Save Embed

25GF Score

Molecular Partners AG MLLCF

Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Molecular Partners AG Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Molecular Partners AG's Total Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	-77.364
	=	0.00

Molecular Partners AG's Total Payout Ratio for the quarter that ended in Mar. 2026 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0.01	+	0)	/	-16.695
	=	0.00

Frequently Asked Questions Learn more about Total Payout Ratio →

What does a Total Payout Ratio of 0.00 mean?

Molecular Partners AG (MLLCF) has a Total Payout Ratio of 0.00 as of Jul. 09, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Molecular Partners AG and its competitors.

Is Molecular Partners AG's Total Payout Ratio too high?

Molecular Partners AG's current Total Payout Ratio is 0.00. Overall, Molecular Partners AG has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Molecular Partners AG's Total Payout Ratio compare to VRTX and REGN?

Molecular Partners AG's Total Payout Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Payout Ratio for a Biotechnology company?

A good Total Payout Ratio depends on the Biotechnology industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Payout Ratio mean?

A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Molecular Partners AG and its competitors. Molecular Partners AG's current Total Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Molecular Partners AG stock overvalued right now?

Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.44, compared to a current price of $3.80 — trading 763.6% above its estimated fair value. The current Total Payout Ratio is 0.00. Molecular Partners AG's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Payout Ratio calculated?

Total Payout Ratio is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Total Payout Ratio is 0.00 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Molecular Partners AG (MLLCF) Overvalued in 2026?

Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued. The current stock price of $3.80 is trading 763.6% above its estimated GF Value™ of $0.44. GuruFocus considers Molecular Partners AG to be Significantly Overvalued.

Key valuation signals for MLLCF:

Total Payout Ratio: 0.00
GF Value™: $0.44 vs. price of $3.80 (763.6% above fair value)
GF Score™: 25/100 with 3 warning signs

No single metric tells the full story. See the MLLCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Molecular Partners AG Business Description

Industry Healthcare Biotechnology

Comparable Companies XSWX:XLS XSWX:BIOV XSWX:MMTX XSWX:ADXN XSWX:SANN XSWX:NWRN VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA XKRX:068270 RPRX ROIV BNTX

Other Exchanges MOLN:USA MOLNz:UK 0QXX:UK 6ML:Germany MOLN:Switzerland

Address Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

25GF Score

Get the complete analysis for MLLCF

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.80

Price

$0.44

GF Value

View MLLCF Analysis

See Total Payout Ratio data for all stocks →